+

DK3368068T3 - Viruslignende partikler med effektiv epitopdisplay - Google Patents

Viruslignende partikler med effektiv epitopdisplay Download PDF

Info

Publication number
DK3368068T3
DK3368068T3 DK16801955.2T DK16801955T DK3368068T3 DK 3368068 T3 DK3368068 T3 DK 3368068T3 DK 16801955 T DK16801955 T DK 16801955T DK 3368068 T3 DK3368068 T3 DK 3368068T3
Authority
DK
Denmark
Prior art keywords
virus
particles
epitope display
efficient epitope
efficient
Prior art date
Application number
DK16801955.2T
Other languages
English (en)
Inventor
Nielsen Morten Agertoug
Adam Frederik Sander Bertelsen
Agerbæk Mette Ørskov
Janitzek Christoph Mikkel
Ali Salanti
Thor Theander
Susan Thrane
Original Assignee
Univ Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Copenhagen filed Critical Univ Copenhagen
Application granted granted Critical
Publication of DK3368068T3 publication Critical patent/DK3368068T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001148Regulators of development
    • A61K39/00115Apoptosis related proteins, e.g. survivin or livin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0012Lipids; Lipoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0208Specific bacteria not otherwise provided for
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK16801955.2T 2015-10-30 2016-10-28 Viruslignende partikler med effektiv epitopdisplay DK3368068T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570699 2015-10-30
PCT/DK2016/050342 WO2017071713A1 (en) 2015-10-30 2016-10-28 Virus like particle with efficient epitope display

Publications (1)

Publication Number Publication Date
DK3368068T3 true DK3368068T3 (da) 2021-02-22

Family

ID=57421596

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16801955.2T DK3368068T3 (da) 2015-10-30 2016-10-28 Viruslignende partikler med effektiv epitopdisplay

Country Status (5)

Country Link
US (1) US11129882B2 (da)
EP (1) EP3368068B1 (da)
DK (1) DK3368068T3 (da)
ES (1) ES2854726T3 (da)
WO (1) WO2017071713A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237115A2 (en) 2017-06-23 2018-12-27 Pathovax Llc CHIMERIC VIRUS-LIKE PARTICLES AND THEIR USES AS SPECIFIC REDIRECTORS OF ANTIGENS OF IMMUNE RESPONSES
CN109251236B (zh) * 2017-07-14 2021-09-28 厦门大学 一种人乳头瘤病毒35型l1蛋白的突变体
CN113396155A (zh) 2018-12-27 2021-09-14 维伊木恩股份有限公司 偶联病毒样颗粒及其作为抗肿瘤免疫重定向剂的用途
KR20230129379A (ko) 2020-10-19 2023-09-08 버이뮨 아이엔씨. 바이러스에 영향받은 조성물 및 암 치료를 위해 이를 사용하여 기존 면역 반응을 재지향시키는 방법

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637166A3 (en) * 1998-10-21 2006-04-12 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virus-like particles for the induction of autoantibodies
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
EP1432443B1 (en) 2001-10-05 2009-01-21 Cytos Biotechnology AG Angiotensin peptide-carrier conjugates and uses thereof
CA2466492A1 (en) 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
DE60229659D1 (de) 2001-11-07 2008-12-11 Cytos Biotechnology Ag Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
AU2003205623A1 (en) 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates
FR2840326B1 (fr) 2002-05-28 2004-07-30 Asselin Chariot mobile d'entree d'etaleur-nappeur et etaleur-nappeur equipe dudit chariot
RU2324704C2 (ru) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
JP4644488B2 (ja) 2002-07-19 2011-03-02 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト アミロイドベータ1−6抗原アレイを含むワクチン組成物
JP2006504653A (ja) 2002-07-19 2006-02-09 サイトス バイオテクノロジー アーゲー グレリン−担体複合体
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
ATE494910T1 (de) 2003-07-10 2011-01-15 Cytos Biotechnology Ag Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
BRPI0507002A (pt) 2004-01-20 2007-06-05 Cytos Biotechnology Ag conjugados veìculos de grelina
WO2005108425A1 (en) 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
EP1751186A2 (en) 2004-06-02 2007-02-14 Cytos Biotechnology AG Carrier conjugates of tnf-peptides
BRPI0511751A (pt) 2004-06-02 2008-01-02 Cytos Biotechnology Ag usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
WO2006027300A2 (en) 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
AU2005286475A1 (en) 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
CA2588274A1 (en) 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
EP1809335A2 (en) 2004-10-25 2007-07-25 Cytos Biotechnology AG Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
US20090123471A1 (en) 2004-10-29 2009-05-14 Cytos Biotechnology Ag T-Cadherin antigen arrays and uses thereof
NZ555590A (en) 2004-12-13 2009-07-31 Cytos Biotechnology Ag Compositions comprising a VLP and IL-15 protein
ZA200707413B (en) 2005-03-18 2009-01-28 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
JP2008543810A (ja) 2005-06-14 2008-12-04 サイトス バイオテクノロジー アーゲー 抗原コンジュゲート及びその使用
CA2621466A1 (en) 2005-09-08 2007-04-05 Kentucky Bioprocessing, Llc Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
WO2007039552A1 (en) 2005-09-28 2007-04-12 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
US8586708B2 (en) * 2005-10-28 2013-11-19 Massachusetts Institute Of Technology Monovalent streptavidin compositions
CA2633161A1 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
KR20080090411A (ko) 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 면역자극 조성물 및 방법
WO2008024427A2 (en) 2006-08-23 2008-02-28 Science & Technology Corporation @ Unm A virus-like platform for rapid vaccine discovery
WO2012048430A1 (en) 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
AU2007336132A1 (en) 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular CCR5 peptide conjugates and uses thereof
WO2008115631A2 (en) 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
WO2009080823A2 (en) 2007-12-20 2009-07-02 Cytos Biotechnology Ag Nerve growth factor conjugates and uses thereof
MX2010009640A (es) 2008-03-05 2010-09-28 Cytos Biotechnology Ag Uso de conjugados de interleucina-1 en el tratamiento de diabetes.
EP2280727A1 (en) 2008-04-22 2011-02-09 Cytos Biotechnology AG Vaccine compositions for the treatment of dengue fever and uses thereof
US20110206727A1 (en) 2008-07-30 2011-08-25 Denis Leclerc Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
BRPI1014718A2 (pt) 2009-06-25 2016-04-12 Glaxonsmithkline Biolog S A polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica
ES2578979T3 (es) 2009-12-31 2016-08-03 Stc.Unm Plásmidos y métodos de expresión de péptidos y selección por afinidad en partículas tipo virus de bacteriófagos de ARN
WO2013003353A2 (en) 2011-06-30 2013-01-03 Stc.Unm Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
WO2011116226A2 (en) 2010-03-17 2011-09-22 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
FR2973032A1 (fr) 2011-03-24 2012-09-28 Commissariat Energie Atomique Peptides aptes a former un complexe covalent et leurs utilisations
US20120259101A1 (en) 2011-04-11 2012-10-11 Li Tan Isopeptide Bond Formation in Bacillus Species and Uses Thereof
GB201214029D0 (en) 2012-08-07 2012-09-19 Queen Mary & Westfield College method
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
WO2014110006A1 (en) 2013-01-10 2014-07-17 Ge Healthcare Dharmacon, Inc. Templates, libraries, kits and methods for generating molecules
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたb型肝炎コアポリペプチド
MX367150B (es) * 2013-07-08 2019-08-07 Novartis Ag Partículas de rotavirus con proteínas de superficie quiméricas.
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
EP3262063B1 (en) 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
GB2535753A (en) 2015-02-26 2016-08-31 The Native Antigen Company Particles comprising fusion proteins
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis

Also Published As

Publication number Publication date
US20190022206A1 (en) 2019-01-24
EP3368068B1 (en) 2020-11-18
EP3368068A1 (en) 2018-09-05
WO2017071713A1 (en) 2017-05-04
ES2854726T3 (es) 2021-09-22
US20200171138A9 (en) 2020-06-04
US11129882B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
HK1246654A1 (zh) 具有有效表位顯示的病毒樣顆粒
HK1255670A1 (zh) Cmv的修飾病毒樣顆粒
EP3209192A4 (en) STEERING MICROENDOSCOPE
HUE045216T2 (hu) Anti-CD79B antitestek és alkalmazási eljárások
HUE048284T2 (hu) Anti-CD40 antitestek és alkalmazásuk
DK3116350T3 (da) Rejsepude
HUE055221T2 (hu) Tetrahidropiranil amino-pirrolopirimidinon és eljárások annak felhasználására
DK3175132T3 (da) Befæstelseselementer
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
GB201406608D0 (en) Virus
IL249823A0 (en) Meningococcus vaccines
HUE042806T2 (hu) Új dextrán-szulfát
PL3092003T3 (pl) Nowe przeciwciało przeciw netrynie-1
KR102101028B9 (ko) 표시장치
IL247159B (en) Components of pcsk9
LT3122378T (lt) Mutantų stafilokokiniai antigenai
HK1258093A1 (zh) 病毒新表位及其用途
LT3178931T (lt) Anti-orai1 antikūnas
LT3628731T (lt) Naujas antipresepsino antikūnas
IL252086A0 (en) Novel methods
DK3368068T3 (da) Viruslignende partikler med effektiv epitopdisplay
DOS2015000092S (es) Pantalla
LT3126391T (lt) Hpa-1a antikūnai
GB201419572D0 (en) Virus
HUE047581T2 (hu) Készítmény
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载